Literature DB >> 35319

Pharmokinetics of 2'-deoxycoformycin in normal and L1210 leukemic mice.

W R McConnell, R L Furner, D L Hill.   

Abstract

Following intravenous administration, 2'-deoxycoformycin (0.25 mg/kg) was rapidly distributed to tissues of both normal mice and mice bearing L1210 leukemia cells and readily eliminated, primarily by urinary excretion. Elimination of 2'-deoxycoformycin from plasma was biphasic, and half-lives for the alpha- and beta-phases of 10 and 33 min for normal mice and 7 and 40 min for L1210-bearing animals. The volume of distribution at steady state was approximately 20 ml, suggesting that the drug was distributed in the total body water for both groups of mice. The kidney, liver, small intestine, spleen, thymus, and L1210 tumor had tissue/plasma ratios greater than or equal to 1 at 15 min after dosing. In both groups, greater than 90% of the dose of 2'-deoxycoformycin was recovered in the urine within 3 hr. As determined by bioautography of urine samples, no detectable metabolism occurred. The presence of the L1210 tumor caused changes in the tissue distribution of 2'-deoxycoformycin. At later time periods, tissues from tumor-bearing mice contained significantly higher levels of this drug when compared to normal mice. However, the tumor was without significant effect on blood levels or urinary excretion of 2'-deoxycoformycin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35319

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Enhanced oral bioavailability of 2'- beta-fluoro-2',3'-dideoxyadenosine (F-ddA) through local inhibition of intestinal adenosine deaminase.

Authors:  R T DeGraw; B D Anderson
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Physiologic model for the pharmacokinetics of 2'deoxycoformycin in normal and leukemic mice.

Authors:  F G King; R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1981-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.